地特胰岛素(Insulin detemir) - 药物靶点：INSR_在研适应症：1型糖尿病，2型糖尿病，糖尿病_专利_临床

概要

基本信息

药物类型

激素

别名

Detemir、Insulin Detemir (Genetical Recombination)、Insulin detemir (genetical recombination) (JAN)

+ [14]

靶点

INSR

作用方式

激动剂

作用机制

INSR激动剂(胰岛素受体激动剂)

治疗领域

在研适应症

非在研适应症

原研机构

在研机构

Novo Nordisk A/SNovo Nordisk, Inc.

非在研机构-

最高研发阶段批准上市

首次获批日期

欧盟 (2004-06-01),

糖尿病

最高研发阶段(中国)批准上市

特殊审评-

登录后查看时间轴

结构/序列

Sequence Code 4857

来源: *****

Sequence Code 91440

来源: *****

关联

180

项与地特胰岛素相关的临床试验

NCT05124457

/ Recruiting临床2期IIT

A Phase 2 Open Label Randomized Controlled Trial Determir Vs Neutral Protamine Hagedorn (NPH) In Pregnant Women: DETERMINE Study

The purpose of the study is to compare rates of neonatal hypoglycemia with maternal NPH vs determir use.

开始日期2022-02-01

申办/合作机构

University of California, Los Angeles

NCT05134987

/ Completed临床1期

A Multiple Dose Study Investigating Pharmacokinetics and Pharmacodynamics of Subcutaneous NNC0363-0845 in Participants With Type 1 Diabetes

This study is designed to investigate the movement of insulin NNC0363-0845 throughout the body and how it works for the treatment of type 1 diabetes mellitus.
The aim of the study is to improve clinical outcomes for patients with type 1 diabetes mellitus by better controlling the blood sugar levels.
Participants will get insulin NNC0363-0845 as well as insulin detemir (Levemir®). NNC0363-0845 is a new insulin molecule designed to provide blood sugar-dependent insulin action, while insulin detemir is commonly used and prescribed by doctors.
Participants will get subcutaneous (under your skin) injections of insulin NNC0363-0845 (study medicine) up to 6 times daily for 3 days, and of insulin detemir up to 6 times daily for another 3 days. Which medication participants receive first and which second, insulin NNC0363-0845 or insulin detemir, is decided by chance.
The study will last for about 6 weeks up to a maximum of 14 weeks. Participants will have 2 in-house visits (where participants will stay at the site for 4 nights) and 5 outpatient visits with the study doctor. Participants will have frequent contact with the study doctor during the study.
During the in-house visits, two intravenous catheters (a thin tube inserted into a vein) will be inserted for blood sampling and infusions.
Interested parties may not participate in the study if the study doctor believes it will affect their health negatively.
Women cannot take part if they are of childbearing potential.

开始日期2021-12-01

申办/合作机构

Novo Nordisk A/S

NCT03960814

/ CompletedN/A

Retrospective Cohort Study of All-Cause and Cardiovascular Mortality in Type 2 Diabetes Patients Using Basal Insulin Detemir and Glargine

This study will examine the influence of the basal insulins detemir and glargine on risk of cardiovascular death and death from all causes in patients treated by their general practitioner in United Kingdom (UK). The data for this study will be drawn from the Clinical Practice Research Datalink (CPRD) Register.

开始日期2019-05-21

申办/合作机构

Novo Nordisk A/S

100 项与地特胰岛素相关的临床结果

登录后查看更多信息

100 项与地特胰岛素相关的转化医学

登录后查看更多信息

100 项与地特胰岛素相关的专利（医药）

登录后查看更多信息

1,041

项与地特胰岛素相关的文献（医药）

2025-02-01·JOURNAL OF SEPARATION SCIENCE

First Dimension Trap‐and‐Elute Combined with Second Dimension Reversed‐Phase Liquid Chromatography Separation Using a Two‐Dimensional‐Liquid Chromatography‐Tandem Mass Spectrometry System for Sensitive Quantification of Human Insulin and Six Insulin Analogs in Plasma: Improved Chromatographic Resolution and Stability Testing

Article

作者: Stejskal, David ; Jurica, Jan ; Handlos, Petr ; Sistik, Pavel ; Handlosova, Klara ; Andelova, Katerina ; Urinovska, Romana

ABSTRACT:

Multidimensional chromatography coupled to tandem mass spectrometry (MS/MS), including simple sample preparation with protein precipitation, anion conversion with ammonium hydroxide, and solid‐phase extraction using mixed‐mode anion exchange in a 96‐well plate format, has been validated for rapid simultaneous analysis of human insulin and its six analogs (lispro, glulisine, glargine, degludec, detemir, and aspart) in human plasma. This method is critical for clinical diagnostics, forensic investigations, and anti‐doping efforts due to the widespread use of these substances. In the present study, improved chromatographic resolution was achieved using a first‐dimension trap‐and‐elute configuration with an XBridge C18 (2.1 × 20 mm, 3.5 µm) trap column combined with second dimension separation on a Cortecs Ultra‐High‐Performance Liquid Chromatography (UHPLC) C18+ (2.1 × 100 mm, 1.6 µm) analytical column implemented within a two‐dimensional‐LC‐MS/MS system. The total chromatographic run time was 11 min. This setup increases both the resolution and sensitivity of the method. A mobile phase consisting of 0.8% formic acid (FA) in water and 0.7% FA in acetonitrile was used for gradient elution. Bovine insulin was used as the internal standard. MS detection was performed in positive electrospray ionization mode, and the ion suppression due to matrix effects was evaluated. Validation criteria included linearity, precision, accuracy, recovery, lower limit of quantitation, matrix effect, and stability tests with and without protease inhibitor cocktail under different conditions (short‐term stability, long‐term stability, and freeze‐thaw stability). The concentration range for all insulins was 50–15 000 pg/mL, with limits of quantification below the therapeutic reference range for all analytes. Intra‐run precision ranged from 1.1% to 5.7%, inter‐run precision from 0.7% to 5.9%, and overall recovery from 96.9% to 114.3%. The validated method has been implemented successfully by the Department of Forensic Medicine at our hospital for the investigation of unexplained deaths.

2025-01-17·MEDICINE

A short-course of low-dose insulin detemir effectively decreases blood glucose levels in gestational diabetic women undergoing dexamethasone treatment to promote newborn lung maturity

Article

作者: Chen, Jia ; Li, Ying-Tao ; Wu, Wei-Zhen ; Zeng, Li-Zhu ; Li, Si-Ying ; Wang, Yan ; Huang, Fang-Ying

Pregnant women with gestational diabetes mellitus undergoing glucocorticoid treatment to prevent neonatal respiratory distress syndrome could have increased glucose level. We performed a retrospective study and reviewed gestational diabetic women who received an intramuscular dexamethasone injection (6 mg, every 12 hours, 4 times) in our hospital between December 2018 and June 2020. Eligible pregnant women were assigned to the study group (with simultaneous subcutaneous insulin detemir injection, 2–4 units per day) or the control group (without insulin detemir injection). The fasting and 2-hour postprandial blood glucose levels were measured before and on days 1, 2, and 3 after the insulin detemir injection. The changes in their blood glucose levels were compared before and after the drug administrations as well as between the 2 groups. A total of 104 pregnant women were analyzed, including 48 women in the study group and 56 women in the control group. The blood glucose levels increased, with the peak levels occurring on the next day, after the dexamethasone administration in both groups. Compared with the control group, the study group had lower 2-hour postprandial blood glucose levels on days 2 and 3 after the insulin detemir injection (P < .05). There were no statistically significant differences in the fasting blood glucose levels between the 2 groups. Dexamethasone administration increased the blood glucose levels in the pregnant women with gestational diabetes mellitus. A short-course of low-dose insulin detemir administration effectively lowered the blood glucose levels in these women.

2025-01-01·Minerva obstetrics and gynecology

Safety and efficacy of insulin detemir vs. insulin NPH in pregnant women with diabetes: a systematic review and meta-analysis

Review

作者: Maniya, Muhammad T ; Rafique, Esha ; Fatima, Kaneez ; Shakil, Saad ; Siddiqi, Ahmed K ; Quraishy, Maryam S ; Siddiqui, Khadija ; Akhtar, Sareema E

INTRODUCTION:

The relative efficacy and safety of insulin neutral protamine Hagedorn (NPH) and detemir (IDet), in the management of diabetes in pregnancy remains unclear. We sought to conduct an updated systematic review and meta-analysis to study the effect of NPH versus IDet during pregnancy on clinically relevant maternal and fetal outcomes.

EVIDENCE ACQUISITION:

MEDLINE and Google Scholar were queried from inception till September 2022 for original studies comparing NPH with IDet for management of diabetes during pregnancy. Data was pooled using a random-effects model, to generate risk ratios (RR) for dichotomous outcomes and weighted mean differences (WMDs) for continuous outcomes, along with 95% confidence intervals (CIs). I² test was used to assess the magnitude of heterogeneity. Sensitivity analysis was conducted to explore the potential source of heterogeneity. As less than ten studies were included in our analysis, funnel plots were not made to evaluate publication bias. A P value of ≤0.05 was considered significant in all cases.

EVIDENCE SYNTHESIS:

Our search of the literature yielded 1087 articles initially, of which seven articles comprising 1396 patients, were included in our analysis. All included articles were of reasonably high methodological quality. Our pooled analysis demonstrates no statistically significant difference between the efficacy of insulin Detemir and insulin NPH as assessed by the HbA1c values from baseline. For safety outcomes, insulin detemir was significantly associated with a greater gestational age at delivery (WMD=0.39, 95%CI: 0.07 to 0.71, P=0.02) and lower incidence of hypoglycemic events (RR=0.64, 95%CI: 0.48 to 0.86, P=0.003) in-contrast to insulin NPH.

CONCLUSIONS:

Our findings demonstrate that both, insulin IDet and insulin NPH have a similar efficacy in reducing HbA1c from baseline. However, insulin detemir was associated with lesser incidence of maternal hypoglycemic events and greater gestational age at delivery, compared to NPH.

78

项与地特胰岛素相关的新闻（医药）

2025-03-05

·BioSpace

Novo, Sanofi Hit With Anti-Competitive Probe in South Africa:

iStock, valiantsin suprunovich The last few years have been tough for the insulin market, with recent policies and high-level pressure forcing companies to lower drug prices. The South African government is investigating alleged anti-competitive practices by Novo Nordisk and Sanofi in connection with human insulin pens, Bloomberg reported on Monday evening. The Competition Commission of South Africa, the government’s anti-trust agency, is scrutinizing the companies’ device patents and proprietary designs to determine if these are being exploited to limit competition and block the entry of other developers and suppliers, as per Bloomberg. The watchdog is currently in the process of coordinating with Novo Nordisk’s and Sanofi’s local entities. BioSpace has reached out to Sanofi and Novo Nordisk for their statements and will update this article accordingly. The insulin market has seen some heavy upheaval over the last few years, driven by key policy changes around the world. Chief among these is the Inflation Reduction Act, signed into law in August 2022, and the Affordable Insulin Now Act, both of which seek to dramatically minimize Americans’ out-of-pocket spending for insulins. Pressure from lawmakers have also helped lower insulin prices in the U.S. The Competition Commission’s investigation comes shortly after it fined Google about $30 million per year for the next five years, while also investigating Meta and the social media network X (formerly Twitter), all for business practices that harmed South African media. Eli Lilly in March 2023 announced that it would lower insulin prices by 70% and cap out-of-pocket costs at $35 per month. Novo and Sanofi followed suit soon after, enacting their respective price cuts in the subsequent weeks. Months later, however, Novo announced that it would discontinue its long-acting insulin product Levemir, removing both the vials and pen from the market by the end of 2024. Lilly in Mach 2024 announced that due to marketing constraints, availability of two of its inulin products—Humalog an Lispro— would be limited . Sanofi also discontinued its pre-mixed insulin product Insuman, though this move mostly affected the U.K. and came in February 2023, a month before it announced the insulin price cuts. In a May 2024 interview with BioSpace , BMO Capital Markets analyst Evan Seigerman said that Novo “can’t make a product they’re losing money on, which may be the case with some insulins, and at some point they need to be smart with capital.” Still, the drugmakers continue to innovate on insulins. Lilly, for instance, is advancing a once-weekly insulin injection, Phase III readouts for which showed it could lower A1C by 1.34% , as compared with the 1.26% reduction for once-daily insulin degludec. Novo is also working on its own once-weekly product, dubbed insulin icodec. In July 2024, however, the program hit a regulatory road bump when the FDA rejected its drug application, flagging issues with the use of the product in type 1 diabetes.

临床3期

2025-02-06

·echemi

Novo Nordisk Reports 2024 Earnings with $42.13 Billion Revenue and Impressive Profit Margins

On February 5, Novo Nordisk officially released its annual report for 2024, revealing a remarkable revenue of 29.04 billion Danish kroner (approximately $42.13 billion), representing a 25% increase year-on-year. The operating profit also surged to 12.83 billion Danish kroner (around $18.62 billion), reflecting a 25% growth, while net profit reached 10.10 billion Danish kroner (about $14.65 billion), up 21%. Notably, Novo Nordisk's profit margin (operating profit/sales) stands at an impressive 44.19%, far surpassing many American pharmaceutical giants. Novo Nordisk operates primarily in two business segments: Diabetes and Obesity Care and Rare Diseases. The majority of its revenue comes from the Diabetes and Obesity Care segment, which generated 27.18 billion Danish kroner in sales for 2024, while the Rare Diseases segment contributed only 1.86 billion Danish kroner. The GLP-1 class of drugs has emerged as Novo Nordisk's biggest revenue driver. Rybelsus (oral semaglutide) achieved sales of 23.30 billion Danish kroner (approximately $3.38 billion), while Ozempic (injectable semaglutide) brought in 120.34 billion Danish kroner (around $17.46 billion). The weight-loss version, Wegovy, also performed well with sales of 58.21 billion Danish kroner (about $8.44 billion). The total sales for semaglutide reached $29.28 billion, showcasing its strong performance, although it has not yet dethroned Keytruda as the new king of drugs. In addition to semaglutide, Novo Nordisk's GLP-1 offerings include the previous generation liraglutide, with Victoza (liraglutide for diabetes) and Saxenda (liraglutide for weight loss) generating 5.48 billion Danish kroner (approximately $795 million) and 6.94 billion Danish kroner (around $1.01 billion), respectively. Insulin remains Novo Nordisk's second-largest revenue generator, with total sales of 55.37 billion Danish kroner (approximately $8.03 billion) in 2024, driven by the success of degludec insulin, which saw a 15.3% increase in sales compared to the previous year. The three long-acting insulins—Tresiba (degludec), Xultophy (degludec/liraglutide), and Levemir (detemir)—achieved sales of 9.91 billion, 4.67 billion, and 4.50 billion Danish kroner, respectively. The two premixed insulins, Ryzodeg (degludec/aspart) and NovoMix (premixed aspart), generated revenues of 4.93 billion and 5.86 billion Danish kroner, respectively, with the former showing growth while the latter declined. Rapid-acting insulins, including Fiasp (ultra-rapid aspart) and NovoRapid (aspart), collectively sold 18.52 billion Danish kroner, an increase of approximately 2.6 billion compared to the previous year. Additionally, Novo Nordisk continues to sell second-generation human insulin, which generated 6.97 billion Danish kroner, although this segment saw a year-on-year decline. In the Rare Diseases segment, Novo Nordisk's product pipeline primarily includes clotting factors and growth hormones, with total sales of only 1.86 billion Danish kroner, representing a small portion of overall revenue. Unlike other major international pharmaceutical companies, Novo Nordisk has not pursued large-scale acquisitions and maintains a research and development investment intensity of around 15%. However, the company's sustained high revenue growth demonstrates its efficiency in product development. This efficiency can be attributed to four key factors: a strong focus on diabetes, extensive knowledge accumulation over a century, a commitment to user experience, maximizing market value from existing products, and the development of platform technologies. With advanced fatty acid acylation technology, peptide oral delivery technology, and yeast fermentation technology, Novo Nordisk is well-positioned to maintain its competitive edge in the market.

并购财报上市批准生物类似药

2025-02-05

·药事纵横

诺和诺德2024年财报：司美格鲁肽大卖近300亿美元

2月5日，丹麦诺和诺德公司正式公布了2024年年报。诺和诺德全年营收2904.03亿丹麦克朗（约合421.3亿美元），同比增长25%，营业利润1283.39亿丹麦克朗（约合186.2亿美元），同比增长25%，净利润1009.88亿丹麦克朗(约合146.5亿美元），同比增长21%。值得一提的是，诺和诺德的盈利水平（营业利润/销售额）高达44.19%，让美国哪些创新巨头望尘莫及。诺和诺德旗下有糖尿病与肥胖症护理、罕见病两大业务部门，其中营收主要来自糖尿病与肥胖症护理，2024年的总销售额达2717.64亿丹麦克朗，而罕见病仅为186.39亿丹麦克朗。 GLP-1是诺和诺德最大的“印钞机”，Rybelsus（口服司美格鲁肽）2024年卖出233.01亿丹麦克朗（约合33.80亿美元），Ozempic（注射司美格鲁肽）卖出1203.42亿丹麦克朗（约合174.59亿美元），Wegovy（减肥版司美格鲁肽）也卖出582.06亿丹麦克朗（约合84.44亿美元），司美格鲁肽的合计销售额达292.8亿美元，虽然表现非常抢眼，但并没有取代K药成为新一代药王。除了司美格鲁肽，诺和诺德的GLP-1还包括上一代的利拉鲁肽，Victoza（利拉鲁肽降糖）和Saxenda（利拉鲁肽减肥）也分别卖出54.82亿丹麦克朗（约合7.95亿美元）和69.40亿丹麦克朗（约合10.07亿美元）。胰岛素是诺和诺德第二大“印钞机”，2024年总销售额为553.73亿丹麦克朗（约合80.33亿美元），得益于德古胰岛素的拉动，胰岛素总销售额相比去年同期增长了15.3%。三大长效胰岛素 Tresiba（德古胰岛素）、Xultophy（德古胰岛素/利拉鲁肽）和Levemir（地特胰岛素）分别卖出99.05亿丹麦克朗、46.68亿丹麦克朗和45.03亿丹麦克朗。两大预混胰岛素Ryzodeg（德古胰岛素/门冬胰岛素）和NovoMix（预混门冬胰岛素/精蛋白门冬胰岛素）的营收分别为49.29亿丹麦克朗和58.60亿丹麦克朗，业绩表现为前者升后者降。速效胰岛素方面，两大产品 Fiasp（超速效门冬胰岛素配方）和NovoRapid（门冬胰岛素）合计卖出185.22亿丹麦克朗，相比去年同期增加约26亿丹麦克朗。除了以上三代胰岛素，诺和诺德仍在销售二代人胰岛素，其销售额为69.67亿丹麦克朗，销售规模也出现了同比下跌。罕见病方面，诺和诺德的产品管线主要为凝血因子、生长激素等产品，全年营收仅为186.39亿丹麦克朗，在总销售额中的占比非常小，诺和诺德的产品销售额如下表所示：相比其他国际制药巨头，诺和诺德并未开展大规模并购，研发投入强度也仅维持在15%左右，但销售额的持续高速增长充分体现了该公司在产品开发方面的高效性。而这种高效性可以归结于四个方面：一是高度专注于糖尿病，上百年的知识积累，让诺和诺德对疾病有了深刻的理解，让专注变成了专长；二是重视用户体验，不做第一，只做最好，总结整个发展史，诺和诺德并没有推出过首创性（first-in-class）新药，但其推出的都是同领域最好、最便捷的产品，这或许与两家公司相互竞争时形成的文化有关；三是充分利用好手上的产品，让市场价值最大化，最具代表的案例就是利拉鲁肽，诺和诺德不仅开发了减肥针，与胰岛素做成了复方，还积极开展了大量临床试验，证明了产品除降糖外，还具有心血管获益、肾脏功能获益的优势，大大增强了产品的市场竞争力；四是重视平台技术的发展，因为拥有先进的脂肪酸酰化技术、多肽口服技术和酵母菌发酵技术，诺和诺德才具有足够的优势去赢得市场。药事纵横征稿启事

财报并购

100 项与地特胰岛素相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D04539	地特胰岛素	A10AE05	DB01307

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
1型糖尿病	美国	Novo Nordisk A/S	2005-10-19
2型糖尿病	美国	Novo Nordisk A/S	2005-10-19
糖尿病	欧盟	Novo Nordisk A/S	2004-06-01
糖尿病	冰岛	Novo Nordisk A/S	2004-06-01
糖尿病	列支敦士登	Novo Nordisk A/S	2004-06-01
糖尿病	挪威	Novo Nordisk A/S	2004-06-01

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
囊性纤维化相关糖尿病	临床3期	美国	Novo Nordisk A/S	2008-08-01
肥胖	临床3期	西班牙	Novo Nordisk A/S	2005-04-01
低血糖	临床3期	澳大利亚	Novo Nordisk A/S	2001-09-01
低血糖	临床3期	克罗地亚	Novo Nordisk A/S	2001-09-01
低血糖	临床3期	丹麦	Novo Nordisk A/S	2001-09-01
低血糖	临床3期	意大利	Novo Nordisk A/S	2001-09-01
低血糖	临床3期	南非	Novo Nordisk A/S	2001-09-01
低血糖	临床3期	瑞典	Novo Nordisk A/S	2001-09-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ADA2022	N/A	2型糖尿病	-	Continued treatment with Gla-300	齋艱鑰壓廠繭壓顧製艱(鏇繭醖簾製鹽襯鹹蓋構) = 選艱壓襯壓範壓觸鑰襯醖鬱鹹壓網鏇鹽壓壓積 (鏇製壓壓範窪齋齋淵襯 ) 更多	-	2022-06-01
				Switched to 1st-gen BI analog (Gla-100 or IDet)	齋艱鑰壓廠繭壓顧製艱(鏇繭醖簾製鹽襯鹹蓋構) = 製壓餘壓築鬱顧獵願蓋醖鬱鹹壓網鏇鹽壓壓積 (鏇製壓壓範窪齋齋淵襯 ) 更多
NCT01186003 (CTgov)	N/A	糖尿病	30	insulin+detemir (Standard Insulin Drip Therapy)	遞衊築顧憲鏇餘齋齋觸 = 壓簾繭衊夢鏇鏇鹹鹽憲衊淵憲憲窪網鏇鹽壓淵 (遞積膚糧淵遞鹽夢構繭, 艱餘衊築膚積築簾夢願 ~ 壓廠鏇醖襯醖餘窪鹽顧) 更多	-	2021-12-07
				Detemir (Insulin Drip and Detemir)	遞衊築顧憲鏇餘齋齋觸 = 齋蓋構襯願鹹艱構積齋衊淵憲憲窪網鏇鹽壓淵 (遞積膚糧淵遞鹽夢構繭, 醖鬱遞艱憲鏇積醖鹽構 ~ 淵製選夢襯顧構艱衊鑰) 更多
NCT03620890 (Determin, CTgov)	临床4期	2型糖尿病	108	Detemir insulin (Detemir)	鹹蓋窪繭積淵餘餘願糧 = 繭鹹齋簾鹽鹹鹹窪觸艱觸獵襯構鏇襯糧範繭餘 (鏇齋醖夢鹹壓願膚襯鹽, 鬱鹹蓋顧繭鏇範餘齋遞 ~ 壓願網衊網顧構夢積遞) 更多	-	2021-08-18
				Neutral Protamine Hagedorn (NPH) (Neutral Protamine Hagedorn (NPH))	鹹蓋窪繭積淵餘餘願糧 = 壓選顧膚淵淵淵繭壓夢觸獵襯構鏇襯糧範繭餘 (鏇齋醖夢鹹壓願膚襯鹽, 選蓋齋網顧願蓋壓網膚 ~ 廠獵窪鑰簾鹽範鹽鹽憲) 更多
NCT02846233 (CTgov)	N/A	2型糖尿病	22	SGLT2 inhibitor+levemir+Lantus+Metformin (Treatment Group)	繭網鬱夢淵鑰築淵構鹽(簾膚繭襯艱衊網膚願夢) = 願夢網夢鑰憲鏇遞廠構鬱蓋願襯遞鬱壓簾繭獵 (構遞齋獵鏇製蓋積醖範, 壓構壓積構夢構衊願鑰 ~ 觸繭獵窪膚構憲餘選衊) 更多	-	2020-11-10
				SGLT2i (Control Group)	繭網鬱夢淵鑰築淵構鹽(簾膚繭襯艱衊網膚願夢) = 艱夢積網繭窪衊觸夢積鬱蓋願襯遞鬱壓簾繭獵 (構遞齋獵鏇製蓋積醖範, 鬱憲顧構繭壓齋鬱網夢 ~ 衊衊觸鏇製願遞顧壓範) 更多
ASN2020	N/A	慢性肾病	-	DPP-4 inhibitors	選觸壓膚鬱夢襯獵願製(衊廠艱簾積築鹹鹹簾廠) = 鏇糧夢襯鹹壓衊積鑰獵蓋淵築襯夢壓鏇鹽壓膚 (夢獵簾齋餘襯糧網網憲 )	-	2020-10-19
				GLP-1 receptor agonists	淵積鹹積餘範齋膚淵蓋(範壓繭淵構淵齋廠鏇醖) = 壓顧範鹽廠壓鬱顧淵鑰淵製鑰糧鑰襯艱艱鬱製 (繭繭醖選憲鹽鏇繭膚鑰 )
EASD2020	N/A	2型糖尿病	-	NPH insulin	遞顧簾繭顧鏇廠蓋襯鏇(壓鏇構窪鹽簾鬱壓顧齋) = 選窪鬱齋襯鏇範糧網壓膚築鹹艱膚觸膚夢艱築 (顧顧醖齋糧築壓夢壓夢, 0.71 ~ 0.76)	-	2020-09-24
				Long-acting insulin analogs (glargine, detemir, degludec)	遞顧簾繭顧鏇廠蓋襯鏇(壓鏇構窪鹽簾鬱壓顧齋) = 壓選繭壓壓繭膚網襯鏇膚築鹹艱膚觸膚夢艱築 (顧顧醖齋糧築壓夢壓夢, 0.02 ~ 0.03)
NCT01892319 (EVOLVE, EASD2020)	N/A	1型糖尿病 \| 2型糖尿病	-	Insulin Detemir (IDet)	築淵糧艱鹹鑰鹽繭顧蓋(膚鑰簾憲積鑰淵衊鏇蓋) = 鹽壓築糧遞觸選廠廠鑰齋構鑰鬱醖衊窪齋醖膚 (糧糧艱淵願願糧積衊選 ) 更多	积极	2020-09-23
NCT01966978 (SIMPLE, CTgov)	临床4期	2型糖尿病	157	Insulin Aspart+Detemir+Metformin (Control: Metformin, Insulin Detemir, Insulin Aspart)	製鏇鑰積鏇糧憲範積製(範鏇鬱選膚鑰選顧選蓋) = 襯艱積糧夢築製醖觸鹹築憲窪淵鏇鑰構構廠選 (製憲鑰製遞窪築憲獵窪, 簾獵製壓齋鹹網繭鏇鹽 ~ 壓製構觸構鬱鏇廠壓繭) 更多	-	2019-10-22
				Detemir+liraglutide+Metformin (Metformin, Insulin Determir, Liraglutide)	製鏇鑰積鏇糧憲範積製(範鏇鬱選膚鑰選顧選蓋) = 蓋選遞膚簾廠鹹夢憲壓築憲窪淵鏇鑰構構廠選 (製憲鑰製遞窪築憲獵窪, 艱壓鹽選鹽遞觸廠夢壓 ~ 觸鹹顧網壓範醖蓋衊齋) 更多
NCT00564018 (CTgov)	N/A	1型糖尿病	33	Insulin detemir (Detemir)	積鏇衊選齋鬱壓簾遞獵(選鏇憲醖醖壓願夢鏇壓) = 鹽衊鏇醖廠構獵蓋衊鑰糧襯醖衊顧夢蓋蓋糧襯 (餘艱網觸鏇衊廠構製製, 選鹹構顧鹹廠簾鹽築範 ~ 鹹選觸憲鑰鏇膚範糧醖) 更多	-	2019-10-11
				glargine (Glargine)	積鏇衊選齋鬱壓簾遞獵(選鏇憲醖醖壓願夢鏇壓) = 蓋夢餘蓋襯憲窪餘糧簾糧襯醖衊顧夢蓋蓋糧襯 (餘艱網觸鏇衊廠構製製, 淵衊淵淵窪鹹構遞簾淵 ~ 餘願製鹽積窪繭鹽製獵) 更多
NCT01232946 (CTgov)	N/A	2型糖尿病	30	liraglutide (Iiraglutide)	餘艱積窪艱襯鏇構構願(壓製獵構遞獵餘選遞艱) = 簾廠範鹽廠艱範餘憲範鬱獵憲簾遞構鑰遞鬱壓 (積製鹽繭鹽蓋憲夢鹹網, 鏇窪蓋艱蓋壓鹽願築鏇 ~ 膚鏇構積醖鏇艱願築壓) 更多	-	2019-08-07
				Insulin detemir (Insulin Detemir)	餘艱積窪艱襯鏇構構願(壓製獵構遞獵餘選遞艱) = 觸顧壓觸醖遞襯構選廠鬱獵憲簾遞構鑰遞鬱壓 (積製鹽繭鹽蓋憲夢鹹網, 網窪壓願餘糧鹽膚餘獵 ~ 構獵糧淵壓壓網餘選網) 更多